Drug Profile

ND 047

Alternative Names: ND-047; ND040-42

Latest Information Update: 28 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Numab
Developer Boehringer Ingelheim; Numab
Class Antibodies; Antineoplastics; Immunoglobulin Fv fragments; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Sep 2024 No recent reports of development identified for research development in Gastrointestinal-cancer in Germany (Parenteral)
05 Feb 2024 No development reported for Lung cancer in Germany (Parenteral) (Numab pipeline, February 2024)
08 Jul 2020 Boehringer Ingelheim and Numab Therapeutics enters into a research collaboration and worldwide licensing agreement

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com